Cardiology Today

About Cardiology Today

Stay current with cardiovascular medicine without the time commitment. Every morning, we deliver concise audio summaries of the latest original research from top cardiology journals. Top 5 breakthrough studies briefed in under 5 minutes (perfect for your commute or between patients). PubMed links included for full articles. Perfect for cardiologists, cardiothoracic surgeons, cardiac nurses, researchers, and healthcare workers who need to stay informed but lack time to scan multiple journals daily. For educational and reference purposes only. Not intended as medical advice.

Publisher

Deconstructed Cardiology

Category

health & fitness · science

Language

en

Explicit

No

First episode

1 Sept 2025

Latest episode

9 Sept 2026

Latest episodes

358 episodes in the feed.

1. 

   9 Sept 2026

   New Model Predicts Heart Failure Risk in Healthy Adults 09/09/26

   Welcome to Cardiology Today – Recorded September 09, 2026. This episode summarizes 5 key cardiology studies on topics like L. D. L. cholesterol and risk estimation. Key takeaway: New Model Predicts Heart Failure Risk in Healthy Adults. Article Links: Article 1: Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry. (Circulation) Article 2: Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model. (European heart journal) Article 3: Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model. (European heart journal) Article 4: Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model. (European heart journal) Article 5: Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/new-model-predicts-heart-failure-risk-in-healthy-adults-09-09-26/ Featured Articles Article 1: Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42360276 Summary: Undertreatment and delayed treatment of aortic stenosis are common, and these issues are associated with increased mortality. The American Heart Association Target: A. S. registry is the first national registry specifically established to provide data and evaluate quality in upstream care processes for patients with aortic stenosis. It includes randomly selected patients from 58 sites with moderate or severe aortic stenosis. This registry directly addresses existing quality gaps in aortic stenosis management by tracking critical aspects of patient care. Article 2: Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41810961 Summary: Patients with established atherosclerotic cardiovascular disease are at high risk for developing heart failure, and current guideline-recommended models do not include incident heart failure in their risk assessment. This study developed and externally validated the S. M. A. R. T. two-H. F. model to predict incident heart failure specifically in patients with atherosclerotic cardiovascular disease. The S. M. A. R. T. two-H. F. model was developed using data from 7698 individuals with established atherosclerotic cardiovascular disease, including coronary, cerebrovascular, peripheral artery disease, or abdominal aortic aneurysm. This model provides a new tool to identify high-risk individuals for incident heart failure, enabling targeted preventative interventions. Article 3: Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41810943 Summary: Heart failure presents a significant and growing public health challenge. This study developed and validated S. C. O. R. E. two-H. F., a model for heart failure risk estimation in European adults over 40 years without previous cardiovascular disease. The sex-specific, competing risk-adjusted S. C. O. R. E. two-H. F. models were derived from 611778 individuals across 25 prospective cohorts in 14 countries, observing 21818 incident heart failure events. The model includes age, smoking status, systolic blood pressure, antihypertensive treatment, type two diabetes, and body mass index as predictive factors. Article 4: Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41810940 Summary: Heart failure with preserved ejection f

2. 

   9 Sept 2026

   AI Electrocardiogram Screens Chagas Disease 09/09/26

   Welcome to Cardiology Today – Recorded September 09, 2026. This episode summarizes 5 key cardiology studies on topics like cardiomyocytes and electrocardiogram. Key takeaway: AI Electrocardiogram Screens Chagas Disease. Article Links: Article 1: HNRNPK Lactylation Amplifies Inflammation and Exacerbates Myocardial Ischemia/Reperfusion Injury by Regulating Jag2 Splicing. (Circulation) Article 2: Overcoming Intrinsic Barriers in Myofibroblasts Permits Efficient Cardiac Reprogramming After Infarction. (Circulation) Article 3: YAP Promotes Microtubule Growth to Facilitate Sarcomere Disassembly in Adult Cardiomyocytes. (Circulation) Article 4: Opportunistic Screening for Chagas Disease Using an Artificial Intelligence-Enabled ECG: Prospective Evaluation of Feasibility and Diagnostic Accuracy. (Circulation) Article 5: COL1A1-Enhanced CD44/SLC7A11 Interaction and Cystine Uptake Result in CD34+ Foam-Like Macrophage Accumulation in Transplant Arteriosclerosis. (Circulation) Full episode page: https://podcast.explainheart.com/podcast/ai-electrocardiogram-screens-chagas-disease-09-09-26/ Featured Articles Article 1: HNRNPK Lactylation Amplifies Inflammation and Exacerbates Myocardial Ischemia/Reperfusion Injury by Regulating Jag2 Splicing. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42708184 Summary: The study identified that myocardial ischemia/reperfusion injury involves profound metabolic reprogramming and lactate accumulation. It uncovered that lactylation, a lactate-derived posttranslational modification, links this metabolic stress to aberrant R. N. A. splicing and cardiac inflammation. The R. N. A.-binding protein HNRNPK, or heterogeneous nuclear ribonucleoprotein K, was found to mediate this connection. This reveals a critical regulatory pathway for inflammatory gene expression in the context of ischemia/reperfusion injury. Article 2: Overcoming Intrinsic Barriers in Myofibroblasts Permits Efficient Cardiac Reprogramming After Infarction. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42708181 Summary: The study demonstrated that direct reprogramming of cardiac fibroblasts into induced cardiomyocytes offers a promising strategy for heart regeneration. It revealed that after myocardial infarction, quiescent cardiac fibroblasts activate and differentiate into myofibroblasts, which drive pathological cardiac fibrosis. The research established that converting these injury-activated myofibroblasts into induced cardiomyocytes can simultaneously alleviate fibrosis and replenish lost cardiomyocytes. This indicates that overcoming intrinsic barriers in myofibroblasts is crucial for achieving efficient cardiac reprogramming. Article 3: YAP Promotes Microtubule Growth to Facilitate Sarcomere Disassembly in Adult Cardiomyocytes. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42578265 Summary: The study discovered that the protein YAP, Yes Associated Protein, actively promotes microtubule growth in adult cardiomyocytes. This promotion of microtubule growth facilitates the disassembly of sarcomeric structures. Sarcomere disassembly was found to be essential for adult cardiomyocytes to dedifferentiate into a fetus-like state, enabling successful cell division. These findings clarify a key regulatory mechanism coordinating cardiomyocyte dedifferentiation, cell cycle progression, and sarcomere reorganization. Article 4: Opportunistic Screening for Chagas Disease Using an Artificial Intelligence-Enabled ECG: Prospective Evaluation of Feasibility and Diagnostic Accuracy. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42576808 Summary: The study demonstrated the feasibility of opportunistic screening for Chagas disease using an artificial intelligence-enabled electrocardiogram model. It established the diagnostic accuracy of this A. I.-E. C. G. model, which was further enhanced with three epidemiological questions for improved detection. This approach was found to enable

3. 

   9 Sept 2026

   Macrotroponin I: Lower Mortality Risk 09/09/26

   Welcome to Cardiology Today – Recorded September 09, 2026. This episode summarizes 5 key cardiology studies on topics like Dilated cardiomyopathy and high-risk genotypes. Key takeaway: Macrotroponin I: Lower Mortality Risk. Article Links: Article 1: Tozorakimab to Prevent COPD Exacerbations. (The New England journal of medicine) Article 2: Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution in Tet2 Clonal Hematopoiesis. (Circulation) Article 3: Macrotroponin Complexes and Risk of Cardiovascular Events. (Circulation) Article 4: Arrhythmic Risk Stratification According to LGE Corridors and Genetics in Nonischemic Dilated Cardiomyopathy. (Circulation) Article 5: An Updated Evidence Assessment of the Genetic Causes of Dilated Cardiomyopathy. (Circulation) Full episode page: https://podcast.explainheart.com/podcast/macrotroponin-i-lower-mortality-risk-09-09-26/ Featured Articles Article 1: Tozorakimab to Prevent COPD Exacerbations. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42708515 Summary: Tozorakimab is a monoclonal antibody that inhibits interleukin-33 activity, a key mechanism implicated in the pathogenesis of chronic obstructive pulmonary disease. This therapeutic approach targets the dysregulated signaling in patients who continue to experience exacerbations despite standard-of-care inhaled maintenance therapy. The OBERON and TITANIA phase three trials investigated tozorakimab for preventing exacerbations in adults with chronic obstructive pulmonary disease who were current or former smokers and had a history of exacerbations. The clinical focus is on providing a new preventative option for this high-risk patient population. Article 2: Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution in Tet2 Clonal Hematopoiesis. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42708224 Summary: The study found that TET2 (tet methylcytosine dioxygenase two) clonal hematopoiesis impairs glycolysis in macrophages. This impaired glycolysis leads to defective efferocytosis, consequently resulting in impaired plaque resolution within atherosclerotic plaques. The data showed that TET2 clonal hematopoiesis promotes atherosclerosis progression. These mechanisms were observed to impair plaque remodeling and regression even under conditions of low-density lipoprotein lowering. Article 3: Macrotroponin Complexes and Risk of Cardiovascular Events. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42708217 Summary: The study found that macrotroponin complexes were present in a general population cohort of 19499 participants, with macrotroponin I found in 0.8 percent and macrotroponin T in 0.2 percent. Results showed that macrotroponin I was associated with a lower risk of all-cause mortality, with a hazard ratio of 0.61 and a 95 percent confidence interval of 0.46 to 0.80. This association for macrotroponin I also extended to cardiovascular mortality, showing a hazard ratio of 0.52 with a 95 percent confidence interval of 0.30 to 0.90, even after adjusting for cardiac troponin levels and confounders. No significant association was observed between macrotroponin T and clinical outcomes. Article 4: Arrhythmic Risk Stratification According to LGE Corridors and Genetics in Nonischemic Dilated Cardiomyopathy. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42708210 Summary: The study found that late gadolinium enhancement (L. G. E.) corridors, assessed through cardiac magnetic resonance imaging, were an independent predictor of major ventricular arrhythmic events in nonischemic dilated cardiomyopathy, showing a hazard ratio of 2.1 with a P value less than 0.001. High-risk genotypes were also identified as an independent predictor, with a hazard ratio of 2.0 and a P value less than 0.001. Patients exhibiting both L. G. E. corridors and high-risk genotypes faced a five-fold higher risk of major ve

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

1 ratings

Contact Cardiology Today

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.